NICE Guidance - May 2011
The National Institute of Health and Clinical Excellence has published new guidance for the month of May 2011. This month there is one clinical guideline, one technology appraisal and one public health guidance that impact upon primary care.
The Common mental health disorders clinical guideline (QRG) offers advice on the care and treatment of adults who have common mental health disorders, with a particular focus on primary care. It covers depression, generalised anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder and social anxiety disorder.
The Peripheral arterial disease technology appraisal (QRG) reviews the role of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate in the treatment of intermittent claudication in patients with peripheral arterial disease. Naftidrofuryl is recommended as an option while the other three options are not recommended.
The Preventing type 2 diabetes public health guidance (QRG) aims to help prevent type 2 diabetes among populations and communities of adults who are at high risk. Several risk factors for developing type 2 diabetes are explored and strategies to promote a healthy diet and greater physical activity are recommended.
Action: Clinicians should be aware of these recommendations and implement any necessary changes to practice.
« MeReC Extra 49 | FDA complete ARB cancer review » |
Leave a Comment